Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Ascend Vitality vs Medro

Ascend Vitality
Graded #307

Lower grade

vs+2.700000000000003
Medro
Graded #252

Higher grade

The verdict

Medro takes it — 63.6/100 to 60.9/100.

Medro grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Medro (Medro Health Technologies, Inc.) is a telehealth brand whose GLP-1 program offers compounded semaglutide and tirzepatide, plus brand-name GLP-1s when eligible, via a partner medical group and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
50
50
Dose & formulationMedro +2
75
77
Clinical oversightAscend Vitality +3
74
71
Labs & monitoringEven
52
52
FulfillmentMedro +27
65
92
Contract termsAscend Vitality +4
37
33
Ascend Vitality · left barMedro · right bar

The numbers

MetricAscend VitalityMedro
WeighScore60.9/10063.6/100
GradeCC
Scorecard rank#307#252
Semaglutide$199/mo (compounded)$199/mo (compounded)
Tirzepatide$299/mo (compounded)$299/mo (compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualYesInjection only
Ascend Vitality

Graded #307 · C

Strengths

  • Both injectable and needle-free oral tablet forms of semaglutide and tirzepatide
  • LegitScript certified
  • Transparent cash-pay pricing with cancel-anytime subscription
  • Legal entity and address publicly disclosed (Ascend Vitality LLC, Sheridan, WY)

Where it loses points

  • All medications are compounded — FDA does not review compounded drugs for safety/effectiveness
  • No named compounding pharmacy partner disclosed
  • No public state-by-state availability list (homepage cites exclusions: LA, MS, KS, NM, WV)
  • Per-dose/titration pricing not published; only 'starting at' prices shown
Medro

Graded #252 · C

Strengths

  • Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
  • LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
  • No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
  • Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).

Where it loses points

  • Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
  • Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
  • Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard